Floatz logo

Lifileucel

Metastatic Bladder Urothelial Carcinoma

Roswell Park Cancer InstituteCell therapyPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

38 Active assets in the Metastatic Bladder Urothelial Carcinoma cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Nagoya University
Phase 3BB
Atezolizumab
KaliVir Immunotherapeutics
Phase 3BB
Carboplatin
Jonsson Comprehensive Cancer Center
Phase 2BB
Nivolumab
Nagoya University
Phase 3BB
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Fred Hutchinson Cancer Center
Phase 2BB

View all 50 →

Same molecule, other indications

Lifileucel is also rated in:

melanomaDormant
BB
Indicative ·
66 / 100
View asset →
cutaneous melanomaDormant
BB
Indicative ·
66 / 100
View asset →
cutaneous melanomaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →